"BIO 2025 in Boston serves as a pivotal platform for fostering strategic partnerships within the global biotechnology community. We are excited to return this year to engage with industry leaders and strengthen relationships with key stakeholders. We have made significant progress over the past year with our clinical-stage HDAC inhibitor portfolio, including CS1 and CS014, both indicating promising disease-modifying potential with favorable safety and tolerability profile. There is a growing enthusiasm for innovative treatment approaches for rare cardiovascular and pulmonary diseases, and we believe our HDACi portfolio is well positioned to contribute impactful advances in this space," said Sten R. Sörensen, CEO of Cereno Scientific. 

Sten R. Sörensen, CEO, Rahul Agrawal, CMO & Head of R&D, and Jeppe Øvlesen, member of the Board, will attend. To schedule a meeting with Cereno Scientific register at https://convention.bio.org/partner.

BIO is the world's largest advocacy association representing biotechnology companies, academic and research institutions, state biotechnology centers and related organizations across the US and in more than 30 other nations. They are the organizers of the annual BIO International Convention, the world's largest gathering of the biotechnology industry.

For further information, please contact:

Tove Bergenholt, Head of IR & Communications

Email:  tove.bergenholt@cerenoscientific.com

Phone:  +46 73- 236 62 46 

Sten R. Sörensen, CEO

Email: sten.sorensen@cerenoscientific.com

Phone: +46 73-374 03 74

About Cereno Scientific AB

Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full.

Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as an effective and disease modifying treatment with a favorable safety and tolerability profile for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1's safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 has a favorable safety profile, is well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension.

The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.